Abstract: The invention relates to a non-invasive, simple, inexpensive, quick method to assess embryo competence in vitro by detecting nucleic acid-containing extracellular vesicles in the culture medium of the embryo. The culture medium may be fixed before being stained with propidium iodide and analysed by flow cytometry.

Abstract: The non-invasive method of assessing the reducing potential of culture medium of in vitro cultured embryos as part of an ART procedure serves as an alternative or supportive method to assess the viability of in vitro cultured embryos without doing any harm to the embryos.

Abstract: A device and method for protecting cells, gametes, embryos, and oocytes from the harmful effect of illumination. The device is a culture dish that is optimized to create a dark environment inside of the dish. The culture dish features a base, an exterior wall connected to the outer rim of the base that forms an enclosure, and a lid connected to the exterior wall. The dish is preferably made of polystyrene and lid is preferably made of aluminum foil. The method features the following steps: reducing a room exposure to sunlight, where the cells and embryos are located; covering the room ceiling lighting with color filter-luminaires; shielding the transparent surfaces of the applied aspiration set and test tube from light; applying a colored red-light filter to the IVF workstation; and incubate cells and embryos in a light-protected place.

Abstract: The invention relates to a non-invasive, simple, inexpensive, quick method to assess embryo competence in vitro by detecting nucleic acid-containing extracellular vesicles in the culture medium of the embryo. The culture medium may be fixed before being stained with propidium iodide and analysed by flow cytometry.

Abstract: The non-invasive method of assessing the reducing potential of culture medium of in vitro cultured embryos as part of an ART procedure serves as an alternative or supportive method to assess the viability of in vitro cultured embryos without doing any ham to the embryos.

Abstract: The invention provides an in vitro method for non-invasive preimplantation assessment of an embryo by comprising amplifying and detecting a nucleic acid sequence of interest indicative of a genetic deficiency from a sample taken from the in vitro culture medium of the embryo and assessing the embryo as having a genetic deficiency if the presence of the sequence of interest is detected in the in vitro culture medium of the embryo. The examples show the detection of SNPs relating to the genes MDR1 and prothrombin and the SNP responsible for the Leiden syndrome. The application also mentions the possibility of establishing short tandem repeat (STR) marker profiles of DNA in the culture medium and full genome sequencing of the DNA in the culture medium as a means for determining embryo quality.

Abstract: The invention relates to an industrial process for the preparation of 17-hydroxy-6?,7?;15?,16?-bismethylene-3-oxo-17?-pregn-4-ene-21-carboxylic acid ?-lactone of formula (I), and to the key-intermediates for this process.

Abstract: The present invention relates to a process for the synthesis of the 17-acetoxy-11?-[4-(dimethylamino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione of formula (I): from 3,3-[1,2-etandiyl-bis(oxy)]-oestr-5(10),9(11)-dien-17-one of formula (II):

Abstract: A process for the production of 1-(4-3(R)-[3(S)-(4-fluorophenyl)-3-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone (ezetimibe) according to the following reaction scheme: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) where the substances of the general Formulas II, IV, VI, VIII, IX, X and XI are new, Formula III is a non-isolated intermediate, R1, R2 and R3 are represented by the compounds of Formulas Va-Vd, (Va), (Vb), (Vc), (Vd) and R4 is a silyl, e.g., tert-butyl-dimethyl-silyl, tert-butyl-diphenyl-silyl group.

Abstract: The present invention relates to a process for the synthesis of the known 17-acetoxy-11-?-[4-(dimethyl amino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione (further on CDB-4124) of formula (I) from 3,3-[1,2-ethandiyl-bis(oxy)]-oestr-5(10),9(11)-dien-17-one of formula (II). Compound CDB-4124 belongs to the group of anti-hormones.

Abstract: An industrially easily realizable and economical process comprising only few steps, and built on new intermediates for the production of 1-(4-3(R)-[3(S)-(4-fluorophenyl)-3-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone (ezetimibe) according to the reaction scheme described herein.

Abstract: The invention relates to an industrial process for the preparation of 17-hydroxy-6?,7?;15?,16?-bismethylene-3-oxo-17?-pregn-4-ene-21-carboxylic acid ?-lactone of formula (I), and to the key-intermediates for this process.

Abstract: The present invention relates to a new process for the preparation of beraprost of formula (I) using new intermediates.

Abstract: The present invention relates to a new process for the preparation of beraprost of formula (I) using new intermediates.